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Abstract: Gut microbiome, a new organ; represent targets to alter pharmacokinetics of orally administered drugs. 
Recently, in vitro trials endorsed the idea that orally administered drugs interact and some of their quantity may be taken 
up by normal microbiome during transit through gut. Such transport mechanisms in microbiome may compete for drug 
with the host itself. Currently, no data confirms specific transport system for paracetamol uptake by gut microbiome. In 
vivo trial was conducted in normal healthy male rats (n=36). Paracetamol was administered orally in a single dose of 
75mg/kg to isolate microbial mass after transit of 2, 3, 4, 5 and 6 hours post drug administration. Paracetamol absorbance 
by microbiome was pursued by injecting extracted microbial lysate in RP-HPLC-UV with C18 column under isocratic 
conditions at 207nm using acetonitrile and water (25:75 v/v) pH 2.50 as mobile phase. Paracetamol absorbance 
(14.10±0.75µg/mg of microbial mass) and percent dose recovery (13.16±0.55%) seen at transit of 4 hours was 
significantly higher (P<0.05) compared to other groups. Study confirms the hypothesis of homology between membrane 
transporters of the gut microbiome and intestinal epithelium. Orally administered drugs can be absorbed by gut microbes 
competitively during transit in small intestine and it varies at various transit times. 
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INTRODUCTION 
 
Paracetamol (acetaminophen, N-acetyl-p-aminophenol) 
an OTC (over the counter) drug is administered as 
antipyretic and analgesic in different ailments (Jóźwiak-
Bebenista and Nowak, 2014). Following the oral 
administration it is rapidly absorbed from the 
gastrointestinal tract with systemic bioavailability ranges 
from 70 to 90%. Its rate of oral absorption is 
predominantly dependent on the rate of gastric emptying 
which can be delayed by food (Forrest et al., 1982). 
 
Intestinal microbiome harbors a diversified microbial 
population with more than 3 million genes that are 150 
times more than human genes and regarded collectively as 
a microbial organ. They weigh about 1 kg that equals the 
weight of brain that performs many functions which the 
human host is unable to process individually (Qin et al., 
2010; Dinan et al., 2015). Microbial cell count vary 
consistently along the axis of gut revealing 10
7
 microbes 
per gram of contents in small intestine and 10
11
 to 10
12
 
cells per gram in the colon (O'Hara and Shanahan, 2006). 
Small intestine is major absorptive site for the nutrients 
presents Bacilli, Actinobactria, Actinomycinacae and 
Streptococcaceae in intestinal lumen, attached or 
embedded in intestinal mucus layer and epithelial crypts 
as major inhabitant (Swidsinski et al., 2005). 
These unique populations of microbes are not only vital 
for the distinctive care of health, but also in dispensation 
of exogenous compounds (medicines) intended to rectify 
homeostatic inequities. The comprehension of this latter 
action of the microbiota has changed the idea of 
pharmaceutical-microbiota connections, shifting the novel 
role of only medicines to an obligation of microbiome-
medicine interaction. The microbiota and in particular 
microbiome-encoded enzymes, now represents probable 
intermediate targets to alter drug pharmacokinetics 
(absorption, distribution, metabolism and elimination) to 
subsequently enhance the clinical response. Previously, it 
was considered that the drugs which are having foremost 
absorption from the duodenal portion of the small 
intestine are less likely to be influenced by the gut 
microbes (Gill et al., 2006). Advancement of drug 
discoveries lead to the development of drugs which have 
prolonged stay in the gut and slow release, so these drugs 
are supposed to be more effected by the gut microbiome 
(Sousa et al., 2008). Some researchers have reported the 
alteration in drug absorbance by the gut epithelial cells in 
the presence of gut microbiota (Forsythe and Bienenstock, 
2010; Furrie et al., 2005). However, they didn’t discuss 
the possibility of drug uptake by the gut micro biomes 
itself.  
 
In the absorption of an orally administered drug it must be 
released from the dosage form, dissolved in the GI fluids, *Corresponding author: e-mail: drhaseebanwar@gcuf.edu.pk 
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remain intact in the intestinal lumen and cross the 
intestinal epithelial membrane (Sousa et al., 2008). 
Different anatomical, physiological and biochemical 
factors affect the dissolution, stability absorption and 
presystemic elimination of drugs vary greatly throughout 
the GIT (Lennernas, 2000). Membrane transporters have 
been recognized recently to be important determinants in 
regulating drug pharmacokinetics and pharmacodynamics 
(Rubio-Aliaga and Daniel, 2008). Therefore, Membrane 
transporters (primary and secondary) play key roles in the 
influx and efflux of various nutrients and drugs in gut 
epithelial cells (Kim, 2006). In Gram negative bacteria 
abundantly found in gut, outer membrane OmpC and 
OmpF channels in Escherichia coli (Mortimer and 
Piddok, 1993) OmpC, OmpF and OmpD in Salmonella 
typhi (Toro et al., 1990) and Omp P1 and P2 from 
Haemophilus influenza (Burns and Smith, 1987; Srikumar 
et al., 1997) are involved in protein mediated transport of 
drugs. Passive diffusion and secondary transport 
mechanisms in bacteria may involve uptake of drug into 
cytoplasm (Lewinson et al., 2003; Abdel-Sayed, 1987). 
 
Furthermore, In E. coli, four protein transporters (PTR) 
family members have been characterized: dipeptide and 
tripeptide YdgR or permease A (DtpA), YhiP, YjdL and 
YbgH (Harder et al., 2008) for their proven role in the 
drug pharmacokinetics and pharmacodynamics. All these 
findings emphasize on potentials of modifying the human 
physiological state by “drugging the microbiome” 
(Garber, 2015). These previous studies strongly support 
our hypothesis however the literature is completely 
lacking in any report regarding the drug absorbance by 
these gut microbes in in vivo by targeting the gut 
microbiome with orally administered drug. Results 
presented by Prabhala (Prabhala et al., 2017) showed 
commonly used drugs like bestatin, sulpiride, oseltamivir, 
valacyclovir, ampicillin and levodopa enter the bacterial 
cell by bacterial POTs in E. coli in vitro trials, thereby; 
suggesting similar transporting mechanisms in gut 
microbes can be used for uptake of orally administered 
drug molecules. In the present study, we established that 
the orally administered drug paracetamol (fig. 1) is a 
substrate of gut microbiome due to the fact that several 
gut microbes contain POT (proton-coupled oligopeptide 
transporter) gene and porins in their genome. 
 
MATERIALS AND METHODS 
 
Animals and housing  
Thirty six normal healthy male rats aged 8 to 10 weeks, 
weighing 150-200gm were selected for the current study 
from the animal rearing nursery of Department of 
Physiology, GCUF. The rats were shifted to isolated 
cages with 25±2
o
C temperature with 40-60% humidity 
maintained in the animal station. One week was given to 
the rats for acclimatization on chow maintenance diet 
(CMD) averagely consumed at 48g/kg body weight daily 
(table 1). All the experiments were conducted after the 
due permission from the Ethical Review Board for the use 
of animals in research, Government College University, 
Faisalabad (Ref. No. GCUF/ERC/130). 
 
Fig. 1: Paracetamol 
 
Table 1: Composition of diet 
 
Dietary Contents 
CMD (Chow 
Maintenance Diet) 
Starch 76% 
Protein 10% 
Oil 10% 
Vitamin and Mineral Mixture * 4% 
*Calcium 35%, Folic Acid 0.2%, Copper Sulphate 0.03%, 
Vitamin A 200000i.u, Phosphorus 32% Iron 0.89%, Selenium 
0.08%, Vitamin D 96000i.u, Sodium 9.44, Manganese 0.39%, 
Cobalt 0.39%, Vitamin E 350i.u, Magnesium 8.64, Zinc 0.22%, 
Potassium Iodide 0.87%, Vitamin B 0.6% (Vit. B1 350i.u, Vit. 
B2 85000i.u, Vit. B6 67000i.u, Vit. B12 350i.u). 
 
Fig. 2: Body weight (gm ± SEM) measured in different 
groups: A1; Control (untreated), groups based upon post 
drug sampling time: A2; 2hours, A3; 3hour, A4; 4hours, 
A5; 5hours and A6; 6hours. 
 
In vivo trial was conducted by differentiating the rats into 
the following groups; control A1 (n=6) without any 
treatment and Paracetamol treated groups (n=30) A2, A3, 
A4, A5 and A6 with single oral dose (75mg/kg body 
weight). All the doses were given orally by 16-18 gauge 
feeding tube about 2-3 inches in length. Six rats in each 
treated group A2, A3, A4, A5 and A6 were sacrificed at 
2, 3, 4, 5 and 6hours, respectively and their microbial 
mass from small intestine was collected to separate the 
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pure microbial lysate. Control group (A1) was sacrificed 
at the start of trial to collect small intestine for isolation of 
microbial mass. 
 
Fig. 3: Small intestine length (cm ± SEM) measured in 
different groups: A1; Control (untreated), groups based 
upon post drug sampling time: A2; 2hours, A3; 3hour, 
A4; 4hours, A5; 5hours and A6; 6hours.  
 
Fig. 4: Small intestine weight (gm ± SEM) measured in 
different groups: A1; Control (untreated), groups based 
upon post drug sampling time: A2; 2hours, A3; 3hour, 
A4; 4hours, A5; 5hours and A6; 6hours. 
 
Microbial lysate 
Methods described by (Upadhaya et al., 2012) and (Tong 
et al., 2014) for isolation of gut microbiota were 
employed with some modification. Immediately after 
sacrificing the rats, small intestine was incised from end 
of pyloric sphincter to illeo-caecal junction with sterile 
scalpel and placed in sterile petri dish. Mean small 
intestine length (fig. 3) and weight (fig. 4) was measured. 
Intestine was cut into 5-6cm long segments which were 
incised longitudinally with a sharp sterile scalpel and 
shaken vigorously with forceps in petri dish to remove the 
luminal contents (digesta). Intestinal digesta was shifted 
to 100ml conical flask and weight of the wet content was 
measured (fig. 5). Ten ml of ice cold normal saline was 
added with digesta and vortexed for 5min. To remove the 
mucosally attached microbes, intestinal segments were 
gripped with forceps and were washed by pipetting 
normal saline in petri dish to remove digesta if present. 
Intestinal pieces were returned to petri dish and added 
with normal saline until tissue was submerged and shaken 
vigorously by forceps. Solution was added in conical 
flask while intestinal sections were placed in 25ml falcon 
tubes already filled with 10ml Normal saline and 1ml of 
1mM dithiothreitol (DTT) pre-warmed at 37
o
C. Mixture 
was placed horizontally in orbital shaker at 180 × g for 
40min.  Mixture was vortexed for 1min and solution was 
added in conical flask. Now final solution in original 
conical flask was vortexed for 5min and filtered through 
two, four and eight-layer cheesecloth, respectively in 
clean sterile conical flask. Filtrate was vortexed for 1min 
and passed through a 70 micron nylon mesh filter that was 
centrifuged at 14000 × g for 2min. The supernatant was 
saved and centrifuged at 6000 × g for 20min, supernatant 
was discarded while sediment was suspended with normal 
saline to a volume of 10ml and centrifuged at 6000 × g for 
20min. Supernatant was discarded, and sediment was 
resuspended with normal saline to a volume of 10ml. This 
step was repeated twice to get pellet which was dissolved 
in 1ml ddH2O and centrifuged at 14000 × g for 20min at 
4
o
C to get the pallet of pure microbial mass (fig. 6). 
Finally, microbial mass was added with 2ml acetonitrile 
to lyse the microbes left overnight at -4
o
C then 
centrifuged at 14000 × g for 20min. Supernatant was 
taken and dried with nitrogen gas, it was then dissolved in 
800µl of mobile phase and filtered through membrane 
filters (pore size, 0.45µm, Milli Pore, USA).The filtrate 
was stored at -20
o
C till further analysis.  
 
Fig. 5: Wet content (gm ± SEM) measured in different 
groups: A1; Control (untreated), groups based upon post 
drug sampling time: A2; 2hours, A3; 3hour, A4; 4hours, 
A5; 5hours and A6; 6hours. 
 
HPLC system and conditions 
Method for HPLC was adopted from Franeta et al., 
(2002) with some amendments. Mobile phase was 
prepared by dissolving acetonitrile and water (25: 75 v/v) 
adjusted to pH 2.50 with phosphoric acid. Liquid 
chromatography consisted of HPLC system (Perkin 
Elmer, USA.) attached with Flexer Binary LC pump, 
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UV/VIS LC Detector (Shelton CT, 06484 USA) and 
reverse phase C18 column (5µm, 250 × 4.6mm) 
accompanying oven set at 30
o
C. Chromera software 
version. 4. 1. 2. 6410 was used to analyze data. 
 
Fig. 6: Microbial mass (mg ± SEM) measured in different 
groups: A1; Control (untreated), groups based upon post 
drug sampling time: A2; 2hours, A3; 3hour, A4; 4hours, 
A5; 5hours and A6; 6hours. 
 
Fig. 7: Total paracetamol absorbance (µg ± SEM) by 
whole small intestine microbiome measured in different 
groups: A1; Control (untreated), groups based upon post 
drug sampling time: A2; 2hours, A3; 3hour, A4; 4hours, 
A5; 5hours and A6; 6hours. AB alphabets shows 
significant difference between different groups (P<0.05). 
 
Volume of 10µl was injected at a flow rate of 1.5mL/min 
to measure the drug concentration from calibration curve 
(fig. 10) prepared using pure paracetamol (HPLC grade) 
standards (1, 5, 10, 20, 30, 40 and 50µg/ml) purchased 
from Sigma Aldrich, USA, at given HPLC conditions that 
is 207nm at retention time of 2.16±0.02min with in run 
time of 8 min. 
 
STATISTICAL ANALYSIS 
 
For statistical analysis one way analysis of variance 
(ANOVA) was employed by Graph Pad Prism. 6, setting 
level of significance at P<0.05. 
RESULTS 
 
Mean body weight (fig. 2), small intestine length (fig. 3), 
small intestine weight (fig. 4), wet content weight (fig. 5) 
and total microbial mass (fig. 6) showed no significant 
difference (P>0.05) among control and treated groups. In 
the initial screening no drug was detected in group A1 
(control), A2, A3 and A6 at 0, 2, 3 and 6hours intestinal 
transit time of sampling, respectively. However, the drug 
absorbance was seen only in group A4 at 4hours and A5 
at 5hours after sampling. Total paracetamol absorbance 
was significantly higher (P<0.05) in group A4 at 4hours 
transit time as compared to group A5 at 5hours transit 
time (fig. 7). Maximum paracetamol absorbance (µg/mg) 
of microbial mass (fig. 8) was seen in group A4 as 
compared to the rest of the groups that was significant 
higher (P<0.05). Percent dose recovery was significantly 
higher (P<0.05) in group A4 at 4hours transit time as 
compared to group A5 at 5hours transit time (fig. 9). 
Maximum drug absorption was seen in group A4 at 
4hours of transit time while maximum transit time was 
5hours at which drug was detected. No drug was detected 
at 6 hours transit time.  
 
Fig. 8: Paracetamol absorbance (µg/mg ± SEM)  of 
microbial mass measured in different groups: A1; Control 
(untreated), groups based upon post drug sampling time: 
A2; 2hours, A3; 3hour, A4; 4hours, A5; 5hours and A6; 
6hours. AB alphabets shows significant difference 
between different groups (P<0.05). 
 
DISCUSSION 
 
In the start of the trial, paracetamol was administered to 
rats by gastric tube to ensure homogeneous solution in the 
stomach. Gastric emptying time of paracetamol solution is 
comparable to water.  In next 10 min after oral 
administration about 70% of the paracetamol was 
available for absorption in small intestine as gastric 
emptying time of paracetamol is about 10-15 min in 
solution form, mixed with low caloric diet and high 
caloric diet (Bartholomé, 2015) with systemic 
bioavailability ranging from 70 to 90% (Forrest et al., 
1982). 
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Grouping and sampling time was based on intestinal 
transit time 3.5 ± 1 hour for solution form of drugs that is 
the maximum time of solution retained in small intestine 
for absorption in the systemic circulation. Intestinal transit 
time is an independent parameter irrespective of fed and 
non-fed state (Davis, 1986). It was hypothesized that 
during its passage through small intestine paracetamol 
also interact with resident microbes either present in 
lumen or attached to mucosal walls of small intestine.  
 
Fig. 9: Percentage dose recovery for given dose of 
Paracetamol measured in different groups: A1; Control 
(untreated), groups based upon post drug sampling time: 
A2; 2hours, A3; 3hour, A4; 4hours, A5; 5hours and A6; 
6hours. AB alphabets shows significant difference 
between different groups (P<0.05). 
 
Fig. 10: Calibration curve of paracetamol is linear over 
the concentration range (1-50 µg/ml) studied. 
 
No significant difference (P>0.05) was found among 
control and treated groups in mean body weight (fig. 2), 
small intestine length (fig. 3), small intestine weight (fig. 
4), wet content weight (fig. 5) and total microbial mass 
(fig. 6). Non significant difference between above said 
parameters is a positive indicator as it strengthens our 
trial’s results regarding microbiome absorbance in various 
groups thereby, minimizing experimental errors between 
groups.  
The small intestine is the major site of absorption for 
nutrients in the body. Microbial density is not 
homogenous in small intestine as it is restricted in 
duodenum due to flushing, bile and pancreatic secretions 
(O'Hara & Shanahan, 2006) but increases abruptly in 
ileum (Booijink et al., 2007). In rats microbial 
composition shows community diversity richness 
increases from upper to lower GIT segments. The small 
intestine shows richness in phylum diversification (16 out 
of 21 Phyla) inhabited predominantly by Firmicutes 
mainly Lactobacillus, Turicibacter and Streptococcus (Li 
et al., 2017).  
 
Table 2: Linearity data of Paracetamol 
 
Parameter Paracetamol 
Linearity Range 1-50 µg/ml 
Regression equation  Y= 1647x-318 
Correlation Coefficient (R
2
) 0.9968 
% Recovery 98.12%. 
Reproducibility (%RSD) <2% 0.13 
 
 
Fig. 11: Chromatogram of paracetamol (20µg/ml) 
standard. 
 
Fig. 12: Chromatogram of blank sample 
 
Current study shows that maximum absorbance of 
paracetamol by gut microbes was seen at intestinal transit 
time of 4hours which was reduced as a function of time 
till transit time of 5hours may be due to competitive 
absorption between gut microbes and gut epithelial cells 
of the host. None of the samples at 6hours were detected 
with drug which shows that maximum transit time of 
paracetamol is 5hours and drug absorbance by intestinal 
microbiome is a time dependent response based on 
intestinal transit time.  
 
Results of the current study show that paracetamol is 
absorbed by microbial cells by some unknown 
mechanism either by passive transport or by secondary 
transport. However, paracetamol is absorbed by epithelial 
cells in small intestine through passive transport process 
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(Bagnall et al, 1979). The studies on structural homology 
confirmed the presence of porins in bacterial cell involved 
in the passive transport of different kind of solutes. 
Passive diffusion and secondary transport mechanisms in 
bacteria may involve uptake of drug into cytoplasm 
(Lewinson et al., 2003; Abdel-Sayed, 1987). Recently, 
researchers concluded from their in vitro studies in E. coli 
cell line that POTs and porins found in the bacterial cells 
particularly in E. coli can transport a number of orally 
administered drugs to the bacterial cell. They gave a fair 
suggestion that similar POTs and porins are also present 
in the gut microbiome which will indeed present a similar 
type of interaction of gut microbiome with the orally 
administered drugs (Prabhala et al., 2017).  
 
Fig. 13: Chromatogram showing paracetamol in microbial 
lysate extracted from microbiome after intestinal transit 
time of 5hours. 
 
Moreover, their findings suggest a homology between 
transporting mechanism in bacterial cell membrane and 
epithelial cells of the gut of the host which further 
emerged a possibility of drug uptake competition between 
these two transport mechanisms which may lead to the 
decreased absorption of some drugs in the gut epithelium. 
This recent finding became a base for the current project 
to test this idea in the in vivo experimental models. The 
drug uptake was seen in the paracetamol fed group based 
upon the theory of homology between transporting 
mechanisms in microbial cell and epithelial cell. 
However, the drug uptake was detected at 4 and 5hours 
only which shows that this drug uptake is very well 
related to the drug intestinal transit time. No drug uptake 
was seen in control group, 2, 3 and 6hours which 
endorsed the findings that HPLC-UV analyses are fair 
enough to verify the results. Volume of 10µl for each 
sample was run in triplicate to find the mean peak area at 
retention time of 2.16±0.02min for run time of 8 min. 
HPLC method was validated by linearity (r
2
=0.9968) 
assessed by linear regression analysis which was 
calculated by least square method. Series of working 
solution (7 points) ranging from 1 µg/ml to 50 µg/ml for 
paracetamol were injected in triplicate and mean value of 
peak area was obtained for calibration curve (fig. 10) that 
indicates good correlation exists between peak areas and 
paracetamol concentrations. Accuracy was studied that 
indicate differences between peak area of spiked 
microbial lysate control samples with known 
concentration (20µg/ml) of paracetamol and standard 
working solution. Mean recovery of paracetamol was 
98.12% within the range of 98-100%. Reproducibility 
was 0.13% expressed as relative standard deviation 
(%RSD) <2% obtained by analyzing six replicate of 
20µg/ml showing RSDs value in table 2; are in line with 
Franeta et al., (2002). In current study, maximum dose 
recovery was 13.16±0.55% seen at transit time of 4hours 
that was significantly higher (P<0.05) than 2.09±0.18% at 
transit time of 5hours while bioavailability of paracetamol 
after oral administration is 70 to 90% (Forrest et al., 
1982). Percent dose recovery of paracetamol from gut 
microbial lysate in current study can be a possible answer 
to the missing drug amount in systemic circulation for 
effective therapeutic response. 
 
CONCLUSION 
 
Orally administered paracetamol was absorbed by gut 
microbes through primary as well as secondary transport 
mechanisms maximally at intestinal transit time of 4hours 
which confirms the idea of homology between transport 
mechanisms in microbial membranes and epical 
membrane of epithelial cells in small intestine. However, 
Maximum transit time of paracetamol in small intestine is 
5hours. Rate of drug absorbance by microbes is reduced 
as a function of prolonged intestinal transit time after 
4hours, providing a competitiveness in drug absorbance 
mechanisms in microbes and epithelial cells in small 
intestine of the host. This study led to the development of 
“in vivo microbial drug absorption assay” that has not 
been addressed so far in scientific work. One of the 
possible strategies to increase the bioavailability of orally 
administered drugs may be the inhibition of microbial 
absorbance of drugs by some substance. This also leads to 
the idea to explore the other orally administered drugs 
with a possibility of microbial absorbance in gut. 
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